Oryzon Genomics awarded grant to support preclinical development of ORY-4001 in ALS - BioWorld Online
| ORY Stock | EUR 1.48 0.02 1.33% |
About 62% of Oryzon Genomics' investor base is looking to short. The analysis of current outlook of investing in Oryzon Genomics SA suggests that many traders are alarmed regarding Oryzon Genomics' prospects. The current market sentiment, together with Oryzon Genomics' historical and current headlines, can help investors time the market. In addition, many technical investors use Oryzon Genomics SA stock news signals to limit their universe of possible portfolio assets.
Oryzon |
Oryzon Genomics awarded grant to support preclinical development of ORY-4001 in ALS BioWorld Online
Read at news.google.com
 |
Oryzon Genomics Fundamental Analysis
We analyze Oryzon Genomics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oryzon Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oryzon Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Oryzon Genomics is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Oryzon Genomics SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Oryzon Genomics stock to make a market-neutral strategy. Peer analysis of Oryzon Genomics could also be used in its relative valuation, which is a method of valuing Oryzon Genomics by comparing valuation metrics with similar companies.
Peers
Oryzon Genomics Related Equities
| BKT | Bankinter | 1.72 | ||||
| KOM | Plasticos Compuestos | 0.00 | ||||
| EBRO | Ebro Foods | 0.38 | ||||
| NHH | NH Hoteles | 0.48 | ||||
| HOME | Neinor Homes | 0.59 | ||||
| IAG | International Consolidated | 0.83 | ||||
| CLNX | Cellnex Telecom | 1.31 |
Complementary Tools for Oryzon Stock analysis
When running Oryzon Genomics' price analysis, check to measure Oryzon Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oryzon Genomics is operating at the current time. Most of Oryzon Genomics' value examination focuses on studying past and present price action to predict the probability of Oryzon Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oryzon Genomics' price. Additionally, you may evaluate how the addition of Oryzon Genomics to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges |